A Cautionary Note on Measuring the Duration of FDA Drug and Device Reviews
Year of publication: |
[2021]
|
---|---|
Authors: | Briggeman, Jason |
Publisher: |
[S.l.] : SSRN |
Subject: | Dauer | Duration | Arzneimittel | Pharmaceuticals | Pharmaindustrie | Pharmaceutical industry | Arzneimittelrecht | Pharmaceutical law |
Extent: | 1 Online-Ressource (9 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments June 21, 2017 erstellt |
Other identifiers: | 10.2139/ssrn.3780321 [DOI] |
Classification: | I18 - Government Policy; Regulation; Public Health ; O38 - Government Policy |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Do-it-Yourself Medicine? The Impact of Light Cannabis Liberalization on Prescription Drugs
Carrieri, Vincenzo, (2020)
-
Risky Business : Should the FDA Pay Attention to Drug Prices?
Hyman, David A., (2018)
-
Conflicts of Interest on Expert Committees : The Case of FDA Drug Advisory Committees
Cooper, James C., (2018)
- More ...
-
Klein, Daniel B., (2009)
-
Protecting cultural monuments against terrorism : a comment
Briggeman, Jason, (2009)
-
Protecting cultural monuments against terrorism : a reply
Frey, Bruno S., (2009)
- More ...